<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="10806" end="10811" sStart="10763" offset="43" sid="r7.1.use.v.0638" wn="1" wnkey="use%2:34:01::" annotator="jeneale" text="A standard curve was constructed using dilutions of sodium nitrite, and the absorbance was measured at 550 nm." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="26642" end="26647" sStart="null" offset="22" sid="r7.1.use.v.0764" wn="1" wnkey="use%2:34:01::" annotator="cgozo" text="We have demonstrated, using in vitro methods, that osteoclast precursors exposed to RANKL for 1-2 days can be rendered resistant to maximal osteoclast-inhibitory doses of IFN-?." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="8158" end="8163" sStart="null" offset="73" sid="r7.1.use.v.0143" wn="1" wnkey="use%2:34:01::" annotator="brubin" text="Cultures were stained with the osteoclast-specific marker TRAP using a kit from Sigma (St Louis, USA)." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="8671" end="8678" sStart="null" offset="49" sid="r7.trace.v.0274" wn="2" wnkey="trace%2:35:00::" annotator="jeneale" text="For extremely robust osteoclast cultures, manual tracing and digital quantitation of a photographed osteoclast area was the best measure due to extensive fusion and multinucleation between cells (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="5453" end="5460" sStart="null" offset="150" sid="r8.suggest.v.0727" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="These data may help explain the contradictory findings regarding the effects of IFN-? as an inhibitor of osteoclastogenesis, and also suggest a model of erosive disease in the presence of IFN-? whereby osteoclast precursors are exposed to RANKL before they enter the IFN-?-rich environment." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="2" wnkey="rapid%5:00:02:fast:01" annotator="veweser" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="3619" end="3624" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="veweser" text="With respect to osteoclast formation, IFN-? is known to potently inhibit RANKL-mediated osteoclastogenesis in both spleen-derived macrophage cultures and bone marrow coculture systems [ 19 20 21 ] . It has also been demonstrated that mice defective in IFN-? signaling have a more &lt;b&gt;rapid&lt;/b&gt; onset of arthritis and bone resorption compared with wild-type mice, suggesting a protective role of IFN-? in early arthritis [ 21 22 ] ." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="tofox" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="elstickles" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="comcgeetubb" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="13956" end="13961" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="The &lt;b&gt;rapid&lt;/b&gt; and irreversible effects of IFN-? on osteoclast inhibition indicate a dominant effect of this cytokine over RANKL via induction of monocyte differentiation toward the activated macrophage fate, as opposed to the osteoclast fate, when concomitantly administered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="3619" end="3624" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" annotator="carichter" text="With respect to osteoclast formation, IFN-? is known to potently inhibit RANKL-mediated osteoclastogenesis in both spleen-derived macrophage cultures and bone marrow coculture systems [ 19 20 21 ] . It has also been demonstrated that mice defective in IFN-? signaling have a more &lt;b&gt;rapid&lt;/b&gt; onset of arthritis and bone resorption compared with wild-type mice, suggesting a protective role of IFN-? in early arthritis [ 21 22 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="331" end="337" sStart="null" offset="71" sid="r9.normal.j.0165" wn="1" wnkey="normal%3:00:01::" annotator="veweser" text="Osteoclasts are critical for both the continuous remodeling of normal bone tissue as well as the repair of fractured bones [ 2 ] . During normal bone remodeling, osteoclast-mediated bone resorption is balanced by osteoblast-mediated bone formation, resulting in the maintenance of skeletal bone mass." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="414" end="420" sStart="null" offset="154" sid="r9.normal.j.0804" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="Osteoclasts are critical for both the continuous remodeling of normal bone tissue as well as the repair of fractured bones [ 2 ] . During normal bone remodeling, osteoclast-mediated bone resorption is balanced by osteoblast-mediated bone formation, resulting in the maintenance of skeletal bone mass." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="25285" end="25291" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="In contrast, Wei et al . have demonstrated that pre-osteoclasts do not lose their potential to differentiate into &lt;b&gt;mature&lt;/b&gt; osteoclasts following a similar exposure to IL-4 [ 50 ] . It thus appears that IFN-? anti-osteoclast activity is mediated by inducing terminal differentiation away from the osteoclast lineage, while IL-4 directly interferes with RANKL signaling during osteoclastogenesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="25285" end="25291" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="In contrast, Wei et al . have demonstrated that pre-osteoclasts do not lose their potential to differentiate into &lt;b&gt;mature&lt;/b&gt; osteoclasts following a similar exposure to IL-4 [ 50 ] . It thus appears that IFN-? anti-osteoclast activity is mediated by inducing terminal differentiation away from the osteoclast lineage, while IL-4 directly interferes with RANKL signaling during osteoclastogenesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="24614" end="24620" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Future studies designed to understand IFN-? signaling in &lt;b&gt;mature&lt;/b&gt; osteoclasts are needed to resolve this issue." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="25285" end="25291" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="In contrast, Wei et al . have demonstrated that pre-osteoclasts do not lose their potential to differentiate into &lt;b&gt;mature&lt;/b&gt; osteoclasts following a similar exposure to IL-4 [ 50 ] . It thus appears that IFN-? anti-osteoclast activity is mediated by inducing terminal differentiation away from the osteoclast lineage, while IL-4 directly interferes with RANKL signaling during osteoclastogenesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="24614" end="24620" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Future studies designed to understand IFN-? signaling in &lt;b&gt;mature&lt;/b&gt; osteoclasts are needed to resolve this issue." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="15209" end="15215" sStart="null" offset="150" sid="r9.level.n.0572" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="Pretreatment with lower doses of RANKL was unable to overcome IFN-? inhibition, indicating that resistance to IFN-? required high levels of RANKL pretreatment (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="16588" end="16592" sStart="null" offset="24" sid="r9.late.j.0668" wn="6" wnkey="late%3:00:02::" annotator="brubin" text="These results show that late pre-osteoclasts are capable of signaling via JAK-STAT1, and suggest that signaling events distal to TRAF6 and STAT1 modulate the resistance of these cells to IFN-?." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/ar612.anc" start="3346" end="3351" sStart="null" offset="0" sid="null" wn="1" wnkey="know%2:31:01::" annotator="carichter" text="With respect to osteoclast formation, IFN-? is &lt;b&gt;known&lt;/b&gt; to potently inhibit RANKL-mediated osteoclastogenesis in both spleen-derived macrophage cultures and bone marrow coculture systems [ 19 20 21 ] . It has also been demonstrated that mice defective in IFN-? signaling have a more rapid onset of arthritis and bone resorption compared with wild-type mice, suggesting a protective role of IFN-? in early arthritis [ 21 22 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="15204" end="15208" sStart="null" offset="145" sid="r10.high.j.0521" wn="1" wnkey="high%3:00:02::" annotator="veweser" text="Pretreatment with lower doses of RANKL was unable to overcome IFN-? inhibition, indicating that resistance to IFN-? required high levels of RANKL pretreatment (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="19703" end="19711" sStart="null" offset="125" sid="r11.function.n.0134" wn="2" wnkey="function%1:07:00::" annotator="anfahmy" text="The present results predict that timing of IFN-? exposure will be an important determinant of its biological function during in vivo osteoclastogenesis." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="24828" end="24837" sStart="null" offset="145" sid="r8.1.different.j.0425" wn="1" wnkey="different%3:00:00::" annotator="veweser" text="It is noteworthy to point out that the dominant/irreversible inhibitory effects of IFN-? on osteoclastogenesis are fundamentally different to the transient/reversible inhibitory effects of IL-4 on this process, which are mediated by STAT6 inhibition of NF?B activation [ 49 50 ] . In the present article, we demonstrate that RANKL-induced osteoclastogenesis cannot be recovered following exposure to IFN-?." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="22940" end="22946" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" annotator="veweser" text="Based on the phenotype of knockout mice, it has &lt;b&gt;become&lt;/b&gt; clear that TRAF6 is the critical adapter molecule required for RANK signaling during osteoclastogenesis [ 35 ] . The importance of TRAF6 has been further explored in deletion studies, which correlated its various domains with its osteoclastogenic potential [ 46 ] . A link between IFN-? and RANK signaling via TRAF6 has also been demonstrated in bone marrow cultures, in which IFN-? was shown to accelerate the degradation of TRAF6 [ 38 ] . In our studies, however, we failed to observe this TRAF6 degradation, as its expression remained constant in both short-term and long-term cultures under conditions where IFN-? completely inhibited osteoclastogenesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="22940" end="22946" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" annotator="tofox" text="Based on the phenotype of knockout mice, it has &lt;b&gt;become&lt;/b&gt; clear that TRAF6 is the critical adapter molecule required for RANK signaling during osteoclastogenesis [ 35 ] . The importance of TRAF6 has been further explored in deletion studies, which correlated its various domains with its osteoclastogenic potential [ 46 ] . A link between IFN-? and RANK signaling via TRAF6 has also been demonstrated in bone marrow cultures, in which IFN-? was shown to accelerate the degradation of TRAF6 [ 38 ] . In our studies, however, we failed to observe this TRAF6 degradation, as its expression remained constant in both short-term and long-term cultures under conditions where IFN-? completely inhibited osteoclastogenesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar612.anc" start="7966" end="7971" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" annotator="cgozo" text="IFN-? (10 ng/ml) was &lt;b&gt;added&lt;/b&gt; on various days in some cultures." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="2042" end="2049" sStart="null" offset="921" sid="r11.absence.n.0187" wn="1" wnkey="absence%1:26:00::" annotator="vebatchelder" text="The molecular signals required for osteoclastogenesis have recently been elucidated [ 1 4 5 ] . Receptor-activator of NF?B ligand (RANKL), a tumor necrosis factor superfamily ligand expressed by stromal cells, osteoblasts, and activated T cells, binds to its cognate receptor-activator of NF?B (RANK) receptor on macrophages/monocytes, inducing a signal that gradually transforms the macrophages into osteoclasts over a period of several days [ 6 7 ] . While this interaction occurs largely in the bone microenvironment, it has been shown that monocytes from the spleen, peripheral blood, and synovium are all capable of RANKL-dependent osteoclast formation [ 8 ] . Convincing evidence has been generated indicating that the RANK-RANKL interaction is absolutely required for osteoclastogenesis [ 7 ] ; in the absence of these molecules, osteoclastogenesis cannot occur [ 9 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/ar612.anc" start="16455" end="16462" sStart="null" offset="85" sid="r11.absence.n.0387" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="This result was confirmed by electrophoretic mobility shift assays and the absence of detectable amounts of the STAT1 antagonists SOCS1 and SOCS3 (data not shown)." />
  </sentences>
</list>